
Table of Contents
Cigna pulled back GLP-1 weight-loss coverage for its own employees July 1. Now it says its clients have been doing the same, marking a notable Evernorth GLP-1 coverage downtick across the company’s pharmacy benefits business.
What Cigna Said About This Evernorth GLP-1 Coverage Downtick
On a July 30 earnings call, Cigna President and CEO Brian Evanko said Evernorth Health Services has seen “a slight downtick” in the percentage of employers that cover GLP-1s for weight management.
The Financial Impact of This Trend
“That produces a modest headwind to our 2026 results, which, fortunately, was overwhelmed, or was more than offset, by the strength in specialty in the second quarter,” Evanko said, indicating the company’s broader specialty pharmacy performance cushioned any negative impact from declining GLP-1 coverage rates among its employer clients.
The Scale of GLP-1 Coverage Across Cigna’s Business Lines
Evanko reiterated how only 15% to 20% of insurance branch Cigna Healthcare’s clients cover GLP-1s for weight loss. Cigna said its insurance business works with many smaller employers, a segment that has historically been less likely to offer weight-loss drug coverage given the associated cost pressures.
A Sharp Decline From Evernorth’s Peak Coverage Rate
Roughly 50% of Evernorth’s clients had covered GLP-1s for weight loss as of May 2025, meaning the current downtick represents a meaningful pullback from a much higher coverage rate just over a year earlier, even though the article does not specify the current exact percentage.
Why Cigna Made This Decision for Its Own Employees
“The decision that we made in our employee benefit plan is driven by the exact same set of challenges that many of our clients are facing, specifically where the net cost of the drug is straining the overall affordability of the plan,” Evanko said. This framing positions Cigna’s own internal coverage decision as a direct reflection of the same cost pressures its employer clients are navigating.
What Cigna Employees Retain Access To
Evanko said the Cigna workforce has access to a supplemental discount program for the drugs, as well as clinical programs. GLP-1 coverage for diabetes remains intact, meaning the pullback specifically targets weight-management use rather than diabetes treatment.
A Reversal From Cigna’s Previously Bullish GLP-1 Stance
Prior to Cigna’s pullback, the company had a relatively bullish stance on GLP-1s. Cigna built out a suite of GLP-1 benefit programs for its employer clients, including offerings to cap costs and enable home delivery, representing a significant strategic reversal from its earlier expansive approach to weight-loss drug coverage.
What Could Reverse This Trend
Evanko said the company would reevaluate its internal GLP-1 policy “should drug manufacturers decide to meaningfully discount the net prices they offer,” suggesting drug pricing remains the central variable that could shift Cigna’s coverage decisions going forward, both for its own employees and potentially for how it counsels its Evernorth clients.
What This Evernorth GLP-1 Coverage Downtick Means for the Broader Market
Cigna’s experience reflects a broader affordability challenge facing employers nationwide as GLP-1 drugs for weight management remain expensive despite growing patient demand. Given that Cigna’s own leadership frames its internal policy change as driven by “the exact same set of challenges” facing its clients, this downtick may signal a more widespread pullback in employer-sponsored GLP-1 weight-loss coverage across the industry, not just within Cigna’s own client base.
What to Watch Going Forward
As drug manufacturers face continued pressure over GLP-1 pricing, industry observers will likely watch whether meaningful net price discounts emerge that could reverse this Evernorth GLP-1 coverage downtick, both for Cigna’s own employee benefit plan and for its broader employer client base. Given the significant drop from roughly 50% Evernorth client coverage in mid-2025, the trajectory of this coverage trend could serve as an important indicator of how sustainable employer-sponsored GLP-1 weight-loss benefits prove to be industrywide as costs continue straining plan affordability.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
